Sareum Holdings plc today provides an update on the development of its proprietary TYK2/JAK1 inhibitor SDC-1801 towards first in human trials. We have published research on this which is attached and a snapshot of the research is below.
The specialist drug development company today announced that it has received a final signed report from the Contract Research Organisation that has conducted the preclinical toxicology and safety studies required to file for an exploratory Clinical Trial Authori ....
